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Human leukocyte antigen (HLA) partially matched related donor (PMRD) hematopoietic stem cell trans-
plantation (HSCT) is an effective option for hematological malignancies. In this study, the nonmalignant late
effects of PMRD HSCT were evaluated and compared with HLA-identical sibling donor (ISD) HSCT. Three
hundred thirteen patients (ISD, n ¼ 160; PMRD, n ¼ 153) who survived at least 6 months and received regular
follow-up examinations after their HSCT were enrolled. The 5-year cumulative incidence (SE) of at least one
late effect and multiple late effects was 47.30%  .17% versus 58.21%  .16% (P ¼ .134) and 17.97%  .10% versus
34.28%  .15% (P ¼ .001) for PMRD HSCT recipients versus ISD HSCT recipients, respectively. The cumulative
incidence of keratoconjunctivitis sicca, periodontitis, ankylosis, myalgia, and nephrotic syndrome was lower
among PMRD HSCT recipients compared with ISD HSCT recipients. Severe chronic graft-versus-host disease,
multiple pre-HSCT chemotherapy cycles, female donor, and older age were risk factors for at least one late
effect. Female donor, older age, and long-term immunosuppressive therapy were associated with multiple
late effects. In summary, PMRD HSCT recipients have a lower risk of late effects compared with ISD HSCT
recipients, possibly due to differences in protocols for graft-versus-host disease prophylaxis, and long-term
follow-up after transplantation is recommended.
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Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is one of the most effective options for very high-risk
hematological malignancies, and many patients can survive
for a long period after HSCT [1,2]. As a result, nonmalignant
late effects of HSCT have become the principal threat to the
health of long-term survivors. Bresters et al. [3] reported that
the cumulative incidence of late effects was 93.2% after
a median follow-up time of 7.2 years after HSCT, and Sun
et al. [4] reported that survivors were twice as likely as their
siblings to develop a chronic condition and 3.5 times as likely
to develop severe conditions. HSCT survivors are at risk for
developing cardiopulmonary, endocrine, and musculoskel-
etal late effects [5-9].
A healthy human leukocyte antigen (HLA) identical
sibling donor (ISD) is preferred but is unavailable for many
HSCT patients. Therefore, HLA partially matched related
donors (PMRDs) have become a valuable option. In recent
years, much progress has been made in PMRD HSCT, and
increasing numbers of patients have achieved long-term
survival. The 2-year probabilities of leukemia-free survival
and overall survival for PMRDHSCT recipients at our institute
were reported as 64% to 68% and 71%, respectively [10,11];
therefore, monitoring the health status of these long-term
survivors has become important.
The quality of life of PMRD HSCT recipients was previ-
ously assessed and was comparable with that of ISD HSCT
recipients [12], but no studies have focused on thedgments on page 782.
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13.01.026we evaluated the nonmalignant late effects of PMRD HSCT
and compared these effects with those of ISD HSCT, and the
risk factors for the late effects were examined.
METHODS
Patients
A total of 357 patients received either ISD HSCT if a matched sibling
donor was available (n ¼ 175) or PMRD HSCT from a family donor (n ¼ 182)
between January 2006 and December 2007. Informed consent was obtained
from all patients or their guardians. Forty-four patients (ISD, n ¼ 15; PMRD,
n¼ 29) who died within 6 months after HSCT were excluded (Supplemental
Table 1), and a total of 313 patients who survived at least 6 months and
received regular follow-up evaluations after their HSCT could be enrolled
in this study (ISD, n ¼ 160; PMRD, n ¼ 153). The endpoint of the last follow-
up was June 1, 2012. Detailed medical information on the patients was
collected through retrospective chart reviews and a regularly updated
transplantation program database. The study protocol was approved by the
ethics committee of Peking University People’s Hospital.
Donor Selection and HLA Typing
Donor selection and HLA typing were previously described in detail [13].
To determine HLA-A and HLA-B status, low-resolution DNA techniques were
used. High-resolution techniques were used for HLA-DRB1 typing. All
donorerecipient pairs were typed at the HLA-A, -B, and -DR loci at our
institute. Each patient with PMRD received stem cells from a family member
who shared the one HLA haplotype with the patient but differed to varying
degrees for the HLA-A, -B, and -D antigens of the haplotype, which were not
shared. In addition to typing each donorerecipient pair, HLA typing was
performed for parents and offspring to be strictly analyzed to guarantee true
haploid genetic background. The HLA disparities in the PMRD HSCT cohort
are presented in Table 1.
Transplantation Regimens
The most frequent preconditioning regimen consisted of cytarabine,
busulfan (4 mg/kg/day, days 8 to 6), cyclophosphamide (1.8 g/m2/day,
days 5 to 4), and semustine (250 mg/m2, day 3). Cytarabine
was administered at 4 g/m2/day (days 10 to 9) in the PMRD group and at
2 g/m2/day (day 9) in the ISD group, and rabbit antithymocyte globulin
(ATG; 2.5 mg/kg, days 5 to 2; Thymoglobulin, Sanoﬁ, Lyons, France) was
Transplantation.
Table 1
Patient Characteristics
Variable ISD (n ¼ 160) PMRD (n ¼ 153) P Value
Gender, n (%)
Female 55 (34.4) 61 (39.9) .314
Age at transplantation, yr, median (range) 38 (12-59) 26 (5-54) <.001
Smoking pre-HSCT, n (%) 25 (15.6) 9 (5.9) .006
Diagnosis, n (%)
AL 84 (52.5) 99 (64.7) .002
CML 58 (36.3) 37 (24.2)
MDS 4 (2.5) 14 (9.2)
SAA 5 (3.1) 2 (1.3)
Other 9 (5.6) 1 (.6)
Status at HSCT, n (%)
Standard risk 139 (86.9) 132 (86.3) .876
Donorerecipient gender, n (%)
Female-to-male 58 (36.3) 40 (26.1) .292
Other combinations 102 (63.7) 113 (73.9)
Mismatched HLA-A,-B,-DR, n (%)
0 160 (100.0) 0 (.0) d
1 19 (12.4)
2 58 (37.9)
3 76 (49.7)
Source of stem cell, n (%)
Bone marrow and peripheral blood 150 (93.8) 145 (94.8) .698
Peripheral blood 10 (6.2) 8 (5.2)
Pre-HSCT cycles of chemotherapy, median (range) 4 (1-16) 5 (1-28) .004
Pre-HSCT cumulative corticosteroid dose, mg/m2, median (range)* 461.5 (16.2-3975.0) 1059.1 (16.3-6040.0) .008
HCT-CI scores, n (%)
Low risk (0) 74 (46.3) 57 (37.3) .222
Intermediate risk (1-2) 48 (30.0) 49 (32.0)
High risk (3) 38 (23.8) 47 (30.7)
Acute GVHD, n (%)
Grades III-IV 4 (2.5) 17 (11.1) .002
Chronic GVHD, CI at 5 yr, % (SE)
Total 53.8 (.16) 51.0 (.17) .779
Severe 18.1 (.09) 11.8 (.07) .080
IST duration, d, median (range) 277 (59-2297) 365 (103-2052) .137
Long-term IST, n (%)y 35 (21.9) 14 (9.2) .002
Monitoring in PUIH  6 mo, n (%) 155 (96.9) 146 (95.4) .504
AL indicates acute leukemia; CML, chronic myeloid leukemia; CI, cumulative incidence; MDS, myelodysplastic syndrome; PUIH, Peking University People’s
Hospital & Institute of Hematology; SAA, severe aplastic anemia.
The criterion for statistical signiﬁcance was P < .05.
* Analysis of the pre-HSCT cumulative corticosteroid dose is limited to patients treated with corticosteroid before HSCT.
y Long-term IST was deﬁned as receiving IST 2 years or more.
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regimens consisting of ﬂudarabine (n ¼ 6) or total body irradiation (n ¼ 7),
and a cyclophosphamide plus ATG regimenwas used in patients with severe
aplastic anemia (n ¼ 7) (Supplemental Table 2) [14,15]. All patients received
cyclosporine A, mycophenolate mofetil, and short-term methotrexate for
graft-versus-host disease (GVHD) prophylaxis [10], and GVHDwas treated in
accordance with the common international criteria [16].
Patients were categorized as “standard risk” or “high risk” as previously
described in detail [17]. Pretransplantation comorbidities were evaluated
using the hematopoietic cell transplantation-speciﬁc comorbidity index
(HCT-CI) [18], and there were no signiﬁcant differences between the two
groups. (Table 1)
Post-HSCT Nonmalignant Late Effect Evaluation
Patients were required to undergo a medical evaluation at our institu-
tion or the local hospital at least once a month between 6 and 12 months
after HSCT and biannually or annually thereafter. However, the 6-month,
1-year, and 2-year evaluations were conducted only at our institution. The
investigators contacted the patients receiving follow-up examinations at
the local hospital and updated the transplantation program database
annually. The prevention and surveillance of infections at our institute were
previously described in detail [11,13], and prophylaxis for encapsulated
organism and invasive fungal infections were recommended for patients
with long-term immunosuppressive therapy (IST). The diagnosis of and
preventive practices for late effects followed the recommendations of
international work groups (version 2006) [19], with the exception of some
screening tests such as 1-year thyroid function testing, which were rec-
ommended if relevant symptoms developed. The detailed protocols of this
study are presented in Supplemental Table 3. The diagnosis of some late
effects may trigger the performance of additional screening tests for thefurther late effects. For example, patients experiencing diabetes underwent
screening tests for nephrotic syndrome, and among patients with new
respiratory signs and symptoms and/or chest radiographic abnormalities,
screening tests for late-onset infections were necessary.
Thirty-two common late effects in 10 categories were captured:
1. Late-onset infections (100 days after transplantation): sepsis,
cytomegalovirus, varicella-zoster virus, Pneumocystis carinii pneu-
monia, and other invasive fungal infections
2. Ocular: keratoconjunctivitis sicca and cataracts
3. Dental: periodontitis
4. Ear-nose-throat (ENT): hearing loss
5. Viral hepatitis: hepatitis B and hepatitis C
6. Pulmonary: bronchiolitis obliterans syndrome, diffuse alveolar
hemorrhage, and idiopathic pneumonia syndrome
7. Cardiovascular: coronary artery disease, heart failure, hyperten-
sion, cerebrovascular events, arrhythmia, and peripheral vascular
diseases (peripheral arterial occlusive disease and deep vein
thrombosis)
8. Endocrine: diabetes, hypothyroidism, hyperthyroidism, and gonadal
failure
9. Musculoskeletal: avascular necrosis of the bone, osteoporosis,
ankylosis, myalgia, and muscular atrophy
10. Urinary: chronic kidney disease and nephrotic syndrome
Medical conditions existing before HSCT were excluded. Some diseases,
such as keratoconjunctivitis sicca and bronchiolitis obliterans syndrome,
may be parts of a chronic GVHD; however, chronic GVHD was excluded as
a late effect for the purpose of this analysis [20]. Seven heart failure patients
in this cohort were reported recently [21].
Table 2
Characteristics of New Nonmalignant Late Effects between the ISD and
PMRD Groups
ISD
(n ¼ 160)
n (%)
PMRD
(n ¼ 153)
n (%)
P Value
Late-onset infections (100 d
after HSCT)
Sepsis 4 (2.5) 4 (2.6) 1.000
Cytomegalovirus 2 (1.3) 4 (2.6) .439
Varicella-zoster virus 3 (1.9) 10 (6.5) .039
Pneumocystis carinii pneumonia 5 (3.1) 1 (.7) .215
Other invasive fungal infections 17 (10.6) 17 (11.1) .890
Ocular late effects
Keratoconjunctivitis sicca
syndrome
49 (30.6) 20 (13.1) <.001
Cataract 4 (2.5) 1 (.7) .372
Dental late effects
Periodontitis 14 (8.8) 3 (2.0) .008
ENT late effects
Hearing loss 6 (3.8) 1 (.7) .121
Liver late effects
Hepatitis B 2 (1.3) 3 (2.0) .679
Hepatitis C 1 (.6) 0 (.0) 1.000
Pulmonary late effects
Bronchiolitis obliterans syndrome 11 (6.9) 4 (2.6) .078
Diffuse alveolar hemorrhage 2 (1.3) 2 (1.3) 1.000
Idiopathic pneumonia syndrome 6 (3.8) 5 (3.3) .817
Cardiovascular late effects
Coronary artery disease 1 (.6) 1 (.7) 1.000
Heart failure 3 (1.9) 4 (2.6) .718
Hypertension 9 (5.6) 3 (2.0) .091
Cerebrovascular events 2 (1.3) 3 (2.0) .679
Arrhythmia 1 (.6) 1 (.7) 1.000
Peripheral arterial occlusive
disease
0 (.0) 1 (.7) .489
Deep vein thrombosis 1 (.6) 0 (.0) 1.000
Endocrine late effects
Diabetes 6 (3.8) 8 (5.2) .527
Hypothyroidism 2 (1.3) 1 (.7) 1.000
Hyperthyroidism 0 (.0) 1 (.7) .489
Gonadal failure 13 (8.1) 11 (7.2) .756
Musculoskeletal late effects
Avascular necrosis of bone 5 (3.1) 7 (4.6) .504
Osteoporosis 2 (1.3) 4 (2.6) .439
Ankylosis 14 (8.8) 5 (3.3) .042
Myalgia 11 (6.9) 1 (.7) .004
Muscular atrophy 2 (1.3) 0 (.0) .499
Urinary late effects
Nephrotic syndrome 4 (2.5) 0 (.0) .123
Chronic kidney disease 1 (.6) 3 (2.0) .362
Late effects
No late effect 66 (41.3) 79 (51.6) .002
1 late effect 38 (23.7) 47 (30.7)
2 late effects 56 (35.0) 27 (17.7)
The criterion for statistical signiﬁcance was P < .05.
Figure 1. Cumulative incidence (CI) of at least one late effect after ISD and PMRD
HSCT. The CI was comparable between PMRD and ISD groups (P ¼ .134).
X.-D. Mo et al. / Biol Blood Marrow Transplant 19 (2013) 777e783 779Statistical Analysis
Demographic and clinical characteristics were compared between the
PMRD and ISD groups using the chi-square and Fisher’s exact tests for
dichotomous variables and a Mann-Whitney U test for continuous variables.
The cumulative incidence of late effects was estimated, with death without
a late effect as the competing risk [22]. Time-dependent covariates were
used to model the impact of speciﬁc late effects on other late effects that
subsequently presented after HSCT [20]. To identify risk factors for
nonmalignant late effects, univariate and multivariate Cox regression anal-
yses were performed. A ﬁxed set of variables was used to assess their impact
on late effects, including age, gender, smoking history, HCT-CI score,
underlying disease, stage at diagnosis (standard risk or high risk), pre-HSCT
chemotherapy cycles, pre-HSCT cumulative corticosteroid doses (using the
75th percentile as the cut-off point), donor gender, source of stem cells
(bone marrow plus peripheral blood or peripheral blood), HLA disparity
(PMRD or ISD), conditioning regimens (total body irradiation, no total body
irradiation, ATG, no ATG), acute GVHD (peak grade; at least grade III or less
than grade III), chronic GVHD (peak category; mild to moderate or severe),
and long-term IST for chronic GVHD (2 years or <2 years; IST includedcorticosteroids, calcineurin inhibitors, mycophenolate mofetil, metho-
trexate, or azathioprine).
All factors with P < .1 in the univariate Cox regression analysis were
included in a multivariate Cox proportional hazard regression model, and
P < .05 was considered statistically signiﬁcant. All reported P values were
based on 2-sided hypothesis tests. Data analyses were primarily conducted
with the SPSS software package (SPSS Inc., Chicago, IL), and the R software
package (version 2.6.1, http://www.r-project.org) was used for cumulative
risk analysis.
RESULTS
Patient Characteristics
Table 1 summarizes the demographic and clinical char-
acteristics of the 313 patients in this study. All patients
achieved full donor chimerism after HSCT. The median age at
HSCT was 33 years (range, 5 to 59 years). The median follow-
up period after HSCT was 63 months (range, 6 to 78 months)
for ISD and 63 months (range, 7 to 78 months) for PMRD
HSCT recipients. The probabilities (SE) of 5-year overall
survival, relapse, and transplantation-related mortality for
ISD and PMRD HSCT recipients in this study were 82.47% 
.09% and 79.08%  .11% (P ¼ .492), 16.25%  .09% and
16.36%  .09% (P¼ .958), and 8.13% .05% and 10.46%  .06%
(P ¼ .473), respectively (Supplemental Table 4).
New Post-HSCT Late Effects
The median time to onset of the ﬁrst late effect was
331 days (range, 23 to 1910 days) for PMRD HSCT recipients
and 403 days (range, 20 to 1920 days) for ISD HSCT recipients
(P ¼ .146). Keratoconjunctivitis sicca, periodontitis, myalgia,
and ankylosis were less common in the PMRD group
(Table 2).
The 5-year cumulative incidence (SE) of at least one
late effect was 47.30%  .17% in PMRD HSCT recipients and
58.21%  .16% in ISD HSCT recipients (P ¼ .134) (Figure 1).
Ocular late effects were the most prevalent conditions in
both groups, followed by late-onset infective, endocrine,
musculoskeletal, cardiovascular, and pulmonary late effects.
The 5-year cumulative incidence of keratoconjunctivitis
sicca, periodontitis, ankylosis, myalgia, and nephrotic syn-
drome was signiﬁcantly lower among PMRD HSCT recipients
compared with ISD HSCT recipients. However, late-onset
varicella-zoster virus infections were less common in the
ISD group (Table 3).
Table 3
Cumulative Incidence of New Nonmalignant Late Effects at 5 Years after HSCT between the ISD and PMRD Groups
ISD (n ¼ 160) PMRD (n ¼ 153) P Value*
Cumulative Incidence
Since HSCT
Median Days
to Diagnosis
Cumulative Incidence
Since HSCT
Median Days
to Diagnosis
Late-onset infections (100 d after HSCT) 17.58 235 19.06 249 .710
Sepsis 2.53 776 2.61 449 .950
Cytomegalovirus 1.25 158 2.61 121 .377
Varicella-zoster virus 1.88 130 6.54 246 .040
Pneumocystis carinii pneumonia 3.14 235 .65 1096 .108
Other invasive fungal infections 10.68 262 11.22 227 .878
Ocular late effects 30.65 1198 13.92 1358 <.001
Keratoconjunctivitis sicca syndrome 30.04 1224 13.27 1358 .010
Cataract 1.93 1409 .65 393 .190
Dental late effects
Periodontitis 8.43 1239 1.96 1272 .007
ENT late effects
Hearing loss 3.80 530 .65 1395 .061
Liver late effectsy 1.88 396 1.96 373 .957
Pulmonary late effects 12.17 361 6.56 254 .101
Bronchiolitis obliterans syndrome 6.94 611 2.64 357 .076
Diffuse alveolar hemorrhage 1.25 281 1.31 693 .969
Idiopathic pneumonia syndrome 3.97 347 3.27 238 .812
Cardiovascular late effects 9.45 358 7.84 322 .508
Coronary artery disease .00 1861 .65 731 .983
Heart failures 1.88 277 2.61 452 .661
Hypertension 5.00 379 1.96 289 .093
Cerebrovascular events 1.25 298 1.96 263 .611
Arrhythmia .64 1043 .65 355 .979
Peripheral vascular diseasesz .70 1665 .65 1213 .991
Endocrine late effects 12.56 365 11.86 365 .832
Diabetes 3.75 92 5.32 276 .538
Hypothyroidism 1.27 715 .65 296 .583
Hyperthyroidism .00 d .64 1318 .323
Gonadal failure 7.54 366 6.62 366 .741
Musculoskeletal late effects 16.36 1224 8.62 1123 .110
Avascular necrosis of bone 3.17 731 3.92 1104 .531
Osteoporosis 1.27 754 1.31 1238 .387
Ankylosis 9.12 1227 3.39 1333 .036
Myalgia 7.29 1314 .65 1523 .004
Muscular atrophy .64 1601 .00 d .155
Urinary late effects 3.14 644 1.96 61 .519
Nephrotic syndrome 2.52 673 .00 d .049
Chronic kidney disease .63 36 1.96 86 .294
The criterion for statistical signiﬁcance was P < .05.
* Comparing the cumulative incidence of late effects between the PMRD and ISD group.
y Liver late effects included 5 cases of hepatitis B and 1 case of hepatitis C.
z Peripheral vascular diseases included 1 case of peripheral arterial occlusive disease and 1 case of deep vein thrombosis.
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PMRD group (Table 2), and the 5-year cumulative incidence
(SE) of multiple late effects was 17.97%  .10% in PMRD
HSCT recipients and 34.28%  .15% in ISD HSCT recipients
(P ¼ .001) (Figure 2). The median time interval between the
ﬁrst and the second late effect was 51 days (range, 0 to 1,587
days) for ISD HSCT recipients and 262 days (range, 0 to 1,397
days) for PMRD HSCT recipients (P ¼ .076). The combination
of ocular and musculoskeletal late effects was most
commonly observed (35.4%), followed by the combination of
ocular and ENT late effects (13.9%), ocular and pulmonary
late effects (13.9%), and ocular and infective late effects
(13.9%). The associations between the different late effects
are presented in Table 4.
Risk Factors for Late Effects
Severe chronic GVHD, multiple pre-HSCT chemotherapy
cycles, female donor, and older age were the independent
risk factors for at least 1 late effect. Female donor, older age,
and long-term IST were the independent risk factors
for multiple late effects (at least 2). In addition, female
gender, smoking, higher pre-HSCT cumulative corticosteroid
doses, higher pre-HSCT comorbidity burden (HCT-CI scores),conditioning regimens without ATG, and peripheral blood
stem cells were also risk factors for late effects (Table 5).
DISCUSSION
Several studies have investigated the late effects of allo-
HSCT recipients, and the cumulative incidence of a late
effect among long-term survivors has been reported to be
32% to 93.2% [3,4,20]. To our knowledge, the present study
was the ﬁrst to evaluate nonmalignant late effects of PMRD
HSCT. Our results show that more than 45% of the long-term
survivors suffered from at least 1 late effect after PMRDHSCT.
Although developments in PMRD HSCT techniques have
signiﬁcantly improved long-term survival, the burden of late
effects after HSCT is high. However, the cumulative incidence
of nonmalignant late effects among PMRD HSCT recipients
was lower than that of ISD HSCT recipients, particularly for
multiple late effects. Several explanations might account for
this surprising ﬁnding.
First, age is considered to be an important risk factor
for late effects. Leung et al. [23] found that older age was
independently associated with endocrine events, chronic
pulmonary diseases, cataracts, and osteoporosis. Khera et al.
[20] found that patients older than 50 years were 1.3 times as
Figure 2. Cumulative incidence (CI) of multiple late effects (at least 2) after
ISD and PMRD HSCT. The CI was lower in the PMRD group (P ¼ .001).
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In our study, age was an independent risk factor for ENT,
cardiovascular, and endocrine late effects. The median age of
PMRD HSCT recipients was signiﬁcantly lower than that of
ISD HSCT recipients, which may have contributed to the
lower cumulative incidence of late effects in the PMRD
group. Research on late effects among older PMRD HSCT
recipients should be continued.
Second, chronic GVHD seems to be another important risk
factor for nonmalignant late effects [4,6,20,23-27]. In our
study, we found that severe chronic GVHD contributed to at
least 1 late effect, as observed in previous studies. Although
the use of unrelated or mismatched donors may be a risk
factor for chronic GVHD [28], Lu et al. [11], Wang et al. [29],
and Chen et al. [30] found that the cumulative incidence of
chronic GVHD did not differ signiﬁcantly between PMRD and
ISD cohorts. In our study, no signiﬁcant differences were
observed regarding the cumulative incidence of chronic
GVHD between the PMRD and ISD cohorts, which suggested
that chronic GVHD did not signiﬁcantly increase the risk of
late effects among PMRD HSCT recipients compared with ISD
HSCT recipients. Thus, a comparable cumulative incidence of
late effects between the cohorts was acceptable.
The treatment of chronic GVHD is also considered a risk
factor for late effects [24,31], and in our study, long-term IST
was associated with multiple late effects in multivariateTable 4
Hazard Ratios for New Late Effects after Another Nonmalignant Late Effect That w
Prior Late Effect
after HSCT
Ocular Dental ENT Liver Pulmonary
HR P HR P HR P HR P HR P
Ocular d 5.0 <.01 7.5 .02 .03 .39 1.9 .10
Dental 3.7 <.01 d 2.6 .38 3.3 .28 2.0 .26
ENT 5.2 <.01 2.4 .39 d .1 .80 3.3 .10
Liver .1 .39 3.6 .22 .1 .80 d 2.1 .48
Pulmonary 2.6 <.01 2.5 .15 4.3 .08 2.2 .47 d
Cardiovascular 2.0 .08 7.4 <.01 5.3 .05 2.4 .42 2.0 .20
Endocrine 2.3 <.01 2.6 .07 4.8 .04 .1 .54 2.2 .06
Musculoskeletal 5.2 <.01 3.1 .03 8.1 .01 .04 .53 1.3 .59
Urinary 3.4 .02 .1 .68 .1 .78 .1 .79 1.4 .72
Infective 1.3 .45 1.4 .56 4.4 .05 2.7 .26 3.0 .01
The criterion for statistical signiﬁcance was P < .05. HR indicates hazard ratio.
The results which were statistically signiﬁcant were highlighted in bold and italicanalysis. Although themedian duration of ISTwas comparable
between the ISD and PMRD group, the proportion of recipi-
ents receiving long-term IST (2 years) was signiﬁcantly
higher in the ISD group (Table 1). The trend toward a higher
cumulative incidence of severe chronic GVHD (P ¼ .08) may
contribute to more long-term IST in the ISD group. On the
other hand, ATG, which could reduce the risk of receiving IST
[32], may increase the PMRD group’s probability of being alive
and free of long-term IST. Because of the negative inﬂuence of
IST on late effects, additional screening tests should be
considered in patients under long-term IST.
Third, several studies have demonstrated that the addi-
tion of ATG to GVHD prophylaxis can signiﬁcantly reduce the
cumulative incidence and severity of chronic GVHD after
HSCT [32-36]. Furthermore, Bacigalupo et al. [35] andMilano
et al. [37] observed that ATG could reduce the occurrence of
chronic lung disease after HSCT. In our multivariate analysis,
we found that ATG remained independently associated with
ocular and dental late effects when adjusted for other
parameters, such as age, gender, HLA disparity, duration of
IST, and chronic GVHD. Therefore, we speculate that condi-
tioning regimens including ATG may be associated with
a lower cumulative incidence of late effects among PMRD
HSCT recipients, but the inﬂuence of other factors on the late
effects could not be excluded.
We also found that the development of late effects in one
system might affect the risk for another system (Table 4).
This result suggested that different late effects may share
common risk factors. For example, cardiovascular late effects
were strongly associated with endocrine late effects (hazard
ratio, 2.8; P¼ .01). On the other hand, several late effects may
be parts of a chronic GVHD syndrome. For example, ocular
late effects (particularly keratoconjunctivitis sicca syndrome)
were more common in patients with dental, pulmonary,
urinary, endocrine, or musculoskeletal late effects. Therefore,
the diagnosis of one late effect may indicate the need to
screen for other late effects that are pathophysiologically
related [20,23].
In the multivariate analysis, multiple pre-HSCT chemo-
therapy cycles and higher pre-HSCT cumulative corticoste-
roid doses were also identiﬁed as risk factors for late effects.
We suggest that frequent therapeutic exposure may cause
subclinical abnormalities of several important organs, even
though no acute toxicities have occurred. These patients
were more susceptible to the conditioning regimen and
transplantation-related complications and therefore at
higher risk for late effects.
The major limitations of this study are the lack of normal
control subjects and the collection of data through theas Already Present
Cardiovascular Endocrine Musculoskeletal Urinary Infective
HR P HR P HR P HR P HR P
1.0 .96 2.3 .01 7.4 <.01 3.1 .11 0.7 .37
3.6 .01 2.5 .06 2.7 .03 .1 .64 .9 .80
3.8 .07 4.0 .02 2.7 <.01 .1 .76 3.0 .07
1.8 .57 .1 .54 .1 .53 .1 .79 2.4 .29
1.8 .30 2.4 .03 1.7 .27 1.5 .70 2.4 .01
d 2.8 .01 3.7 <.01 4.0 .09 2.5 .01
2.2 .07 d 4.6 <.01 4.0 .06 .6 .34
2.2 .08 4.1 <.01 d .9 .91 .8 .53
3.5 .09 3.9 .02 1.1 .93 d .7 .71
3.0 .01 .7 .55 1.2 .73 .8 .76 d
type.
Table 5
Multivariate Analysis of Risk Factors for New Nonmalignant Late Effects
Risk Factors Hazard Ratio 95% CI P Value
At least one late effect Age, per decade 1.22 1.07-1.40 .004
Female donor 1.38 1.01-1.89 .042
Pre-HSCT chemotherapy, per cycle 1.07 1.02-1.12 .005
Chronic GVHD, severe 1.86 1.29-2.69 .001
Two or more late effects Age, per decade 1.42 1.16-1.73 .001
Female donor 1.94 1.23-3.06 .004
IST  2 years 2.17 1.35-3.48 .001
Late-onset infections Age, per decade 1.32 1.05-1.66 .019
HCT-CI scores, per risk group* 1.45 1.06-1.99 .021
Ocular late effects Female donor 1.72 1.06-2.81 .030
Conditioning regimens without ATG 2.47 1.46-4.17 .001
IST  2 years 1.92 1.13-3.26 .016
Dental late effects Conditioning regimens without ATG 4.88 1.40-16.95 .013
ENT late effects Age, per decade 2.85 1.22-6.67 .016
Liver late effects Stem cell source, peripheral blood 8.09 1.48-44.20 .016
Pulmonary late effects Chronic GVHD, severe 4.90 2.36-10.19 <.001
Cardiovascular late effects Age, per decade 1.53 1.05-2.21 .025
Higher pre-HSCT cumulative corticosteroid dosey 7.60 3.14-18.41 <.001
Chronic GVHD, severe 3.26 1.35-7.88 .009
Endocrine late effects Age, per decade 2.66 1.34-5.26 .005
Female gender 3.47 1.82-6.63 <.001
Musculoskeletal late effects Female gender 2.64 1.40-4.98 .003
IST  2 years 2.50 1.23-5.06 .011
Urinary late effects Smoking pre-HSCT 5.21 1.25-21.81 .024
The criterion for statistical signiﬁcance was P < .05.
* HCT-CI is separated into 3 risk groups: low (0), intermediate (1-2), and high (3).
y The 75th percentile was used as the cutoff point.
X.-D. Mo et al. / Biol Blood Marrow Transplant 19 (2013) 777e783782retrospective review of clinical records. Although all
patients received HSCT and were followed up in the same
period of time and the results might not be signiﬁcantly
inﬂuenced by these limitations, it would be premature to
derive conclusions regarding the superiority of PMRD over
ISD in terms of late effects. Performing prospective studies
that include a noncancer population, in a larger cohort, and
in an age-adjusted model would help to further evaluate the
late effects among PMRD HSCT recipients. In addition,
despite a median follow-up of more than 5 years after HSCT,
the observation period was not long enough, which may
have led to the low reported cumulative incidence of late
effects with a long latency. It is important to observe
whether the trend of the lower cumulative incidence of
nonmalignant late effects would be conﬁrmed after a longer
follow-up, and we will continue to evaluate the late effects
in our cohort.
In summary, PMRD HSCT recipients have a lower risk of
late effects compared with ISD HSCT recipients, possibly due
to differences in protocols for GVHD prophylaxis, and both
patient populations needed to be followed in the long term
after transplantation. The early identiﬁcation and treatment
of nonmalignant late effects will improve the health status of
long-term survivors.ACKNOWLEDGMENTS
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